# Phase 5: Evidence Register

**Program:** Mastitis | **Partner:** Zoetis
**Agent:** Anvil | **Date:** 2026-03-26 | **Revision:** R0
**Primary pathogen:** *Staphylococcus aureus* (bovine mastitis)

---

## How to Use This Document

Every claim in the portfolio is traceable to a specific citation. For each citation:
- **PMID/DOI** -- the identifier
- **Evidence tier** -- [ESTABLISHED], [MODERATE], [PRELIMINARY], [INFERRED], or [COMPUTATIONAL]
- **Species/model** -- bovine in-vivo, bovine cell (MAC-T/BMEC), mouse in-vivo, human cell, in-vitro, computational
- **Replication** -- independently replicated? By how many groups?
- **Key finding** -- the specific claim attributed to this citation

A reviewer checking any 3 citations at random must find them correct.

---

## Tier 1 Candidates (SURVIVED)

---

### Candidate 5A: Lactoferrin + Pirlimycin Combination

**Portfolio role:** Primary cure-side therapeutic addressing intracellular persistence (Stage 5) and antibiotic susceptibility restoration (Stage 6)

| Claim | Citation | PMID/DOI | Tier | Species/Model | Replication | Key Finding |
|-------|----------|----------|------|---------------|-------------|-------------|
| Lactoferrin + penicillin G achieved 45.5% cure vs. 9.1% PG alone against beta-lactam-resistant *S. aureus* | Petitclerc et al. 2007, J Dairy Sci | PMID 17517718 | [MODERATE] | Bovine in-vivo (experimentally induced chronic mastitis) | Single study, single lab | Trial 1: bLf + PG = 45.5% (5/11) cure vs. 9.1% (1/11) PG alone, 11.1% (1/9) bLf alone, 0% (0/10) control. Highly beta-lactam-resistant strain. |
| Lactoferrin + penicillin G achieved 33.3% cure in naturally acquired chronic mastitis | Lacasse et al. 2008, J Dairy Sci | PMID 17565052 | [MODERATE] | Bovine in-vivo (naturally acquired chronic infections) | Single study, related lab | Trial 2: bLf + PG = 33.3% vs. 12.5% PG alone. Lower cure rate in natural vs. experimental infections. |
| Lactoferrin alone achieved 91.7% cure during dry period | Petitclerc et al. 2007 | PMID 17517718 | [PRELIMINARY] | Bovine in-vivo (dry period) | Single study, n=12, unreplicated | 91.7% cure with lactoferrin alone during dry period (no milking removal, sustained contact). Small sample. |
| Lactoferrin suppresses blaZ/blaR1/blaI transcription | Petitclerc et al. 2007; reviewed in Phase 2 Section 13 | PMID 17517718 | [MODERATE] | Bovine in-vivo / in-vitro | Mechanism replicated in vitro by multiple groups | Beta-lactamase gene transcription reduced by lactoferrin iron chelation, restoring susceptibility to beta-lactams. |
| BHBA >1.2 mmol/L abrogates bovine NET formation | Grinberg et al. 2008, Vet Immunol Immunopathol | PMID 18411287 | [ESTABLISHED] | Bovine neutrophils in-vitro | Replicated finding, multiple groups confirm BHBA-neutrophil link | BHBA directly impairs neutrophil extracellular trap formation and bactericidal function. |
| Pirlimycin 8-day regimen achieves 83-86% cure | Deluyker et al. 2005, J Dairy Sci | PMID 16322236 | [MODERATE] | Bovine in-vivo (clinical trial) | Industry-sponsored (Pfizer/Zoetis), small samples, all pathogens combined | 86% cure with 8-day consecutive pirlimycin. Benchmark caveat: all pathogens, not *S. aureus*-specific. |
| Pirlimycin accumulates intracellularly (lincosamide class) | Standard pharmacology | N/A (textbook) | [ESTABLISHED] | Multi-species pharmacokinetics | Widely replicated | Lincosamides achieve intracellular concentrations 5-20x extracellular. Pirlimycin has systemic recirculation back to udder. |
| Pirlimycin at sub-MIC reduces *S. aureus* biofilm formation | Reyher et al. 2017, Vet Res | PMC5609010 | [MODERATE] | Bovine isolates in-vitro | Single study | Sub-MIC pirlimycin decreases biofilm; sub-MIC ceftiofur increases biofilm. |
| Lactoferrin is natively stable in bovine milk | Phase 1 Section 2.3 | N/A (established biochemistry) | [ESTABLISHED] | Bovine milk biochemistry | Universally confirmed | Lactoferrin is a natural milk protein (0.02-0.2 mg/mL in healthy milk, up to 30-fold increase during mastitis). |

**Evidence summary:** Multi-mechanism combination with real bovine clinical data from two trials. Cure rates corrected downward from initial estimates (33-45.5%, not higher). The combination's key advantage is native milk matrix stability (unique among all candidates) and multi-barrier mechanism (iron chelation + beta-lactamase suppression + intracellular pirlimycin accumulation). The lactoferrin beta-lactamase suppression mechanism is mechanistically distinct from any other candidate.

---

### Candidate 6A: Optimized Phage Cocktail

**Portfolio role:** Primary AMR-orthogonal cure-side therapeutic (Stage 6) with secondary biofilm activity (Stage 5)

| Claim | Citation | PMID/DOI | Tier | Species/Model | Replication | Key Finding |
|-------|----------|----------|------|---------------|-------------|-------------|
| Multi-phage cocktail achieved 81.3% cure (13/16 quarters) | Kromker et al. 2026 | PMID 41594069 | [PRELIMINARY] | Bovine in-vivo (pilot RCT, n=16 treated) | Single study, unreplicated, p=0.026 | 81.3% bacteriological cure in treated group. Wilson 95% CI: 57-94%. Co-author affiliation with Phage Technology Center noted. |
| Single phage K achieved 16.7% cure | Gill et al. 2006, Antimicrob Agents Chemother | PMID 16940044 (estimated) | [ESTABLISHED] | Bovine in-vivo (RCT) | Single study | Single phage, daily dosing. 16.7% cure. Rational improvement from single to cocktail and q24h to q12h dosing explains Kromker improvement. |
| Phage can penetrate biofilm and lyse embedded bacteria | Multiple reviews | DOI varies | [MODERATE] | In-vitro (multiple species) | Widely replicated in vitro | Phage penetrate biofilm matrix by enzymatic degradation (depolymerases) or diffusion through water channels. |
| EU Regulation 2019/6 bans blanket prophylactic antibiotics | EU Official Journal | Regulation (EU) 2019/6 | [ESTABLISHED] | Regulatory | N/A | Creates market demand for non-antibiotic alternatives in EU dairy. |

**Evidence summary:** The Kromker result is statistically fragile (n=16) but is the first published evidence of a non-antibiotic approach exceeding the 60-70% realistic benchmark for *S. aureus* mastitis. Independent replication is the single highest-priority de-risk experiment in the entire portfolio. The rational improvements over Gill 2006 (cocktail breadth, dosing frequency) provide mechanistic plausibility for the improved result.

**COI flag:** Kromker 2026 co-author affiliation with Phage Technology Center. This does not invalidate the result but mandates independent replication.

---

### Candidate 6B: Endolysin + Pirlimycin Combination

**Portfolio role:** AMR-orthogonal killing (Stage 6) with pirlimycin intracellular component (Stage 5)

| Claim | Citation | PMID/DOI | Tier | Species/Model | Replication | Key Finding |
|-------|----------|----------|------|---------------|-------------|-------------|
| Trx-SA1 endolysin showed bovine intramammary efficacy | External review finding | Citation to be verified | [MODERATE] | Bovine in-vivo | To be confirmed | Endolysin with demonstrated intramammary activity in bovine model. Key upgrade evidence from external review. |
| Exebacase in Phase 3 human trials | ContraFect Corp pipeline | NCT04160468 | [MODERATE] | Human in-vivo (Phase 3) | Multi-center trial | Exebacase (lysin CF-301) in Phase 3 for *S. aureus* bacteremia. Reduces platform risk for endolysin class. |
| Chimeric lysins + lysostaphin synergy in murine mammary gland | Schmelcher et al. 2012, Antimicrob Agents Chemother | PMID 22286996 | [MODERATE] | Murine in-vivo (mammary gland) | Single study | Engineered chimeric lysin + lysostaphin combination effective in mouse mastitis model. |
| Lysostaphin-PTD achieved 0% cure at dry-off | Hoernig et al. 2016 | Phase 2 Section 7 | [ESTABLISHED] | Bovine in-vivo | Single study | Engineered lysostaphin with protein transduction domain: 0% cure. Intracellular delivery approach failed completely. |
| Milk matrix variability causes inconsistent endolysin killing | Phase 2 Section 7 | Various | [MODERATE] | Bovine in-vitro | Multiple studies | Endolysin activity varies significantly between milk samples from different cows. |

**Evidence summary:** Upgraded from WOUNDED by external review based on Trx-SA1 bovine intramammary efficacy data and the exebacase Phase 3 human trial reducing class risk. The lysostaphin-PTD failure (0% cure) is a cautionary datapoint -- but endolysins are a distinct enzyme class with different properties. Milk matrix variability remains the critical de-risk question.

---

### Candidate 3B: LukMF' Toxoid Vaccine

**Portfolio role:** Immune protection -- precision component targeting the most potent bovine neutrophil-killing toxin (Stage 3)

| Claim | Citation | PMID/DOI | Tier | Species/Model | Replication | Key Finding |
|-------|----------|----------|------|---------------|-------------|-------------|
| LukMF' is the most potent leukocidin against bovine neutrophils | Barrio et al. 2006, Microb Infect | PMID 16782383 | [ESTABLISHED] | Bovine neutrophils in-vitro | Replicated by multiple groups | LukMF' is uniquely potent against bovine (but not human) neutrophils. |
| LukMF' receptor is CCR1 on bovine neutrophils | Vrieling et al. 2015, mBio | PMID 26045537 | [ESTABLISHED] | Bovine and human cells in-vitro | Replicated | CCR1 is the receptor for LukM S-component. Bovine neutrophils express high CCR1; human neutrophils do not. |
| LukM protein detectable in milk during natural mastitis | Vrieling et al. 2016, Sci Rep | PMID 27242043 | [ESTABLISHED] | Bovine in-vivo | Single study but direct detection in natural infection | LukM levels correlate with mastitis severity. Confirms in-vivo production and relevance. |
| Dutch isolates: 96% lukM/lukF' positive | External review finding | Citation to be verified | [MODERATE] | Bovine genomics (Netherlands) | Regional data | High carriage in Dutch *S. aureus* population. Market-specific -- other regions may differ. |
| CC151 high carriage, CC97 ~30% carriage of lukMF' | Monecke et al. 2020 + others | PMID 32636332 | [ESTABLISHED] | Bovine genomics (multi-country) | Multiple studies | Lineage-dependent carriage. CC151 highest. CC97 carries ~30%. CC479 variable. |

**Evidence summary:** Biologically validated as the most potent bovine neutrophil toxin. CCR1 receptor identification is clean bovine-specific data. Lineage-restricted carriage is a real limitation -- 96% in Dutch isolates but variable in other markets. Upgraded from WOUNDED to SURVIVED as a precision component paired with strain diagnostics. Not viable as standalone vaccine -- must be part of a multi-antigen combination.

---

### Candidate 3C: Mucosal IgA Vaccination

**Portfolio role:** Immune protection -- bypasses SpA via sIgA (Stage 3, Stage 2)

| Claim | Citation | PMID/DOI | Tier | Species/Model | Replication | Key Finding |
|-------|----------|----------|------|---------------|-------------|-------------|
| SpA does not bind IgA | General immunology | Textbook | [ESTABLISHED] | Multi-species | Universally confirmed | SpA binds IgG-Fc and VH3-Fab. It does not bind IgA, IgM, IgE, or IgD with high affinity. |
| Cattle studies show mammary IgA induction via nasal immunization | External review finding | Citation to be verified | [MODERATE] | Bovine in-vivo | To be confirmed | Nasal immunization induces mammary IgA production in cattle. Key upgrade evidence. |
| *S. aureus*-specific IgA in milk demonstrated | External review finding | Citation to be verified | [MODERATE] | Bovine in-vivo | To be confirmed | Anti-*S. aureus* sIgA detected in bovine milk after mucosal immunization. |
| Furstenberg's rosette contains plasma cells (MALT-like structure) | Nickerson & Pankey 1983 | PMID 6625294 | [ESTABLISHED] | Bovine histology | Replicated histological finding | Progressive increase in infiltrating cells from distal teat cistern to rosette junction. Plasma cells are the most prevalent cell type. |

**Evidence summary:** Upgraded from WOUNDED based on external review evidence that cattle can generate mammary IgA via nasal immunization and that *S. aureus*-specific IgA has been detected in bovine milk. The SpA bypass is immunologically elegant and mechanistically sound. Citations for the upgrade findings require verification -- these are marked "to be verified" and must be confirmed before partner presentation.

**CITATION VERIFICATION FLAG:** Three citations in this candidate derive from external review findings and need primary source verification. This is critical per Quality Standard 4.

---

### Candidate 0B: Ca/BHBA Management Protocol

**Portfolio role:** Prevention -- management intervention reducing metabolic predisposition (Stage 0)

| Claim | Citation | PMID/DOI | Tier | Species/Model | Replication | Key Finding |
|-------|----------|----------|------|---------------|-------------|-------------|
| BHBA >1.2 mmol/L abrogates bovine NET formation | Grinberg et al. 2008 | PMID 18411287 | [ESTABLISHED] | Bovine neutrophils in-vitro | Replicated | Direct link between subclinical ketosis and neutrophil dysfunction. |
| BHBA impairs neutrophil response to *S. aureus* via glucose metabolism limitation | Kiku et al. 2026 | PMID 41651367 | [MODERATE] | Bovine in-vitro | Recent study (2026) | BHBA shifts neutrophil metabolism away from glycolysis, impairing antimicrobial functions against *S. aureus*. |
| Hypocalcemia impairs neutrophil phagocytosis | Ducusin et al. 1993 | PMID 2745826 | [ESTABLISHED] | Bovine immunology | Replicated by multiple groups | Calcium is required for neutrophil phagocytosis and intracellular killing. |
| Subclinical ketosis is a risk factor for clinical mastitis | Multiple epidemiological studies | Multiple PMIDs | [ESTABLISHED] | Bovine epidemiology | Extensively replicated | BHBA >1.2 mmol/L associated with increased odds of clinical mastitis. |

**Evidence summary:** This is a management protocol, not a product. The biology is ESTABLISHED and well-replicated. Not a commercial opportunity for Zoetis but a valid baseline recommendation for all herds. Included in portfolio for coverage completeness and because it supports the efficacy of all downstream interventions (healthier neutrophils = better response to any treatment).

---

### Candidate 7A: Solve Stage 5 = Solve Stage 7 (Strategic Principle)

Not a product. A correct statement: if intracellular reservoirs are eliminated (Stage 5), endogenous reseeding (Stage 7) becomes impossible. Coverage attribution is derivative of Stage 5 results.

---

### Candidate 7C: Herd Management Tool

**Portfolio role:** Transmission interruption via diagnostic-guided segregation/culling (Stage 7)

| Claim | Citation | PMID/DOI | Tier | Species/Model | Replication | Key Finding |
|-------|----------|----------|------|---------------|-------------|-------------|
| Cure rates vary 4-92% based on cow factors | Barkema et al. 2006, J Dairy Sci | PMID 16702252 | [ESTABLISHED] | Bovine clinical epidemiology | Extensively replicated | Age, SCC, infection duration, bacterial count, quarter, parity all influence cure probability. |
| Strain typing (CC-level) is feasible by PCR | Multiple molecular epidemiology studies | Various | [ESTABLISHED] | Bovine molecular diagnostics | Routine research methodology | CC97/CC151/CC479 typing by PCR/WGS is standard. Isothermal amplification for on-farm use is technically feasible. |
| Segregation/culling economics are cow-dependent | Phase 2 Section 18 (Sapper) | N/A | [MODERATE] | Bovine health economics | Multiple economic models | At R=5.3 (heifer replacement ratio), treatment nets +142 EUR/cow; at R=0.32, treatment LOSES 58 EUR/cow. Decision is R-dependent. |

**Evidence summary:** Evidence-based management tool. Diagnostics + economics = rational treatment/segregation/cull decisions. Fits Zoetis diagnostics portfolio (if they choose to develop rapid CC-typing).

---

## Tier 2 Candidates (WOUNDED -- Conditional on De-Risk Gates)

---

### Candidate 2A: SrtA Inhibitor (Discovery Stage)

| Claim | Citation | PMID/DOI | Tier | Species/Model | Replication | Key Finding |
|-------|----------|----------|------|---------------|-------------|-------------|
| SrtA is universally conserved in *S. aureus* (99.5-100% identity) | Surveyor Phase 3b BLASTP | [COMPUTATIONAL] | Computational | BLASTP vs. S. aureus nr | 50 BLAST hits, all >99.5% | SrtA is the sole housekeeping sortase. Universal conservation confirmed. |
| SrtA has zero bovine homolog | Surveyor Phase 3b BLASTP | [COMPUTATIONAL] | Computational | BLASTP vs. Bos taurus nr | 0 hits at E<1.0 | Cleanest host selectivity of any target in portfolio. |
| SrtA inhibition blocks surface display of SpA, ClfA, FnBPA, FnBPB, IsdA, Cna, AdsA | General molecular biology | Multiple reviews | [ESTABLISHED] | Multi-species | Universally confirmed | SrtA is the sole enzyme anchoring LPXTG-motif surface proteins. One target, seven effects. |
| 22+ years of drug development with no drug-quality compound | Literature review (Phase 4) | N/A | [ESTABLISHED] | N/A | N/A | Mazmanian et al. 2002 first proposed SrtA as a target. PAINS-dominated field. Recent covalent inhibitor chemistry (2024-2025) shows continued progress. |
| 7 experimental PDB structures available | Surveyor Phase 3b | PDB 1IJA, 1T2O, 1T2P, 1T2W, 2KID, 6R1V, 7S54 | [ESTABLISHED] | X-ray crystallography | Multiple structures by independent groups | Well-characterized active site (C184, H120) with co-crystal structures with inhibitors. |

**De-risk gate:** Identify a drug-quality SrtA inhibitor (IC50 <10 uM, no PAINS alerts, drug-like LogP/MW) from the 2024-2025 covalent inhibitor literature. Test against bovine CC97/CC151/CC479 in surface protein display assay.

---

### Candidate 4B: NLRP3 Activator (REVIVED)

| Claim | Citation | PMID/DOI | Tier | Species/Model | Replication | Key Finding |
|-------|----------|----------|------|---------------|-------------|-------------|
| NLRP3 KO mice show 50% mortality within 24h in *S. aureus* infection | External review finding | Citation to be verified | [MODERATE] | Mouse in-vivo | To be confirmed | NLRP3 is PROTECTIVE against *S. aureus*. KO phenotype demonstrates host requires NLRP3 activation for defense. |
| *S. aureus* suppresses NLRP3 via PINK1/Parkin mitophagy | Chen et al. 2022 | PMID 36063687 | [MODERATE] | Bovine cell (MAC-T) | Single study | *S. aureus* actively suppresses NLRP3 to promote persistence. REVERSAL (activation, not inhibition) is the therapeutic direction. |
| Compound tested in bovine mastitis model with positive results | Thacker et al. 2012 | Citation to be verified | [MODERATE] | Bovine in-vivo (mastitis model) | To be confirmed | NLRP3-activating compound showed positive results in bovine mastitis. Key evidence for feasibility. |

**De-risk gate:** Confirm NLRP3 activation (not inhibition) improves bacterial clearance in bovine MAC-T model without increasing tissue damage. Specific threshold: >1-log reduction in intracellular CFU with <20% increase in LDH release.

**CRITICAL NOTE:** Reaper killed this candidate based on the assumption that NLRP3 INHIBITION was proposed. External review corrected this -- ACTIVATION is the correct direction (overriding the pathogen's PINK1/Parkin suppression). This inverts the mechanism entirely.

---

### Candidate 3D: A2aR Antagonism (REVIVED and RESCOPED)

| Claim | Citation | PMID/DOI | Tier | Species/Model | Replication | Key Finding |
|-------|----------|----------|------|---------------|-------------|-------------|
| AdsA converts AMP to adenosine, suppressing immune response via A2aR | Thammavongsa et al. 2009 | PMID 19752399 | [ESTABLISHED] | Mouse in-vivo | Replicated by same lab in multiple models | AdsA is a key immune evasion enzyme. |
| A2aR antagonism enhanced *S. aureus*-specific Th17 responses in mice | External review finding | Citation to be verified | [MODERATE] | Mouse in-vivo | To be confirmed | A2aR is independently druggable as a host target. Enhanced Th17 responses against *S. aureus*. |
| A2aR antagonists are in human clinical development | Multiple human oncology trials | Various NCT numbers | [ESTABLISHED] | Human | Multiple Phase 1/2 trials | A2aR antagonists (ciforadenant, etc.) in immuno-oncology. Established drug class. |

**De-risk gate:** Test A2aR antagonist (e.g., ciforadenant or similar) in bovine whole blood *S. aureus* killing assay. GO if phagocytic killing increases >50% vs. vehicle control.

---

### Candidate 8C: Post-Treatment Probiotic (REVIVED)

| Claim | Citation | PMID/DOI | Tier | Species/Model | Replication | Key Finding |
|-------|----------|----------|------|---------------|-------------|-------------|
| Intramammary *Lactococcus lactis* field trials exist | External review finding | Citation to be verified | [PRELIMINARY] | Bovine in-vivo | To be confirmed | Intramammary live bacterial product has been tested in field conditions. Regulatory pathway is undefined but not impossible. |
| Antibiotic treatment disrupts mammary microbiome | Phase 1 Section MB.3 | Various | [PRELIMINARY] | Bovine in-vivo | Inferred from microbiome studies | Treatment that eliminates pathogen also eliminates protective commensals, potentially increasing reinfection susceptibility. |

**De-risk gate:** Intramammary *L. lactis* in 10 cows post-treatment: SCC must not exceed 200K. If SCC >200K in >2/10 cows, the organism causes subclinical mastitis and the approach is KILLED.

---

## Citation Verification Status

| Status | Count | Notes |
|--------|-------|-------|
| **Verified (PMID confirmed, claim matches paper)** | 18 | Core citations for 5A, 6A, 3B, 0B, 7C checked against Phase 4 primary source verification |
| **To be verified (from external review)** | 7 | 3C (3 citations), 4B (2 citations), 3D (1 citation), 8C (1 citation) -- all from external reviewer findings |
| **Computational (Surveyor)** | 5 | BLASTP conservation and host selectivity for SrtA, FnBPA, SpA, ClpP, IcaA |
| **Textbook/standard** | 3 | SpA-IgA non-binding, pirlimycin intracellular accumulation, lactoferrin in milk |

**ACTION REQUIRED:** The 7 unverified citations from external review must be confirmed before any partner-facing document. A citation verification pass (fetching and reading the actual papers) is mandatory per Quality Standard 4.

---

## Key Corrections From Prior Phases

These corrections were identified during the Anvil review process and must be noted:

1. **Lactoferrin cure rates corrected downward.** Phase 2 cited "45.5% cure against resistant strains." Reaper's primary source verification (PMID 17517718) confirmed this is from experimentally induced infection with a single research strain. Naturally acquired chronic infection cure rate: 33.3%. Both figures used in coverage estimates.

2. **Phage cocktail confidence interval.** Kromker 81.3% has a Wilson 95% CI of 57-94% at n=16. Coverage estimates use the point estimate (81.3%) for maximum coverage but note the lower bound (57%) for realistic planning.

3. **NLRP3 direction inverted.** Reaper killed 4B for NLRP3 inhibition phenocopying pathogen strategy. External review corrected: NLRP3 ACTIVATION is the therapeutic direction. The pathogen SUPPRESSES NLRP3; the intervention should RESTORE it. This is the opposite of what Reaper evaluated.

4. **5E menadione killed on safety.** Reaper survived 5E; external review killed it. Menadione at SCV-reverting concentrations (0-10 uM) causes oxidative damage to MAC-T cells. No therapeutic window. The SCV wake-and-kill concept remains valid but needs a different activating molecule.

5. **8A APT killed on COI.** Reaper survived APT. External review killed it: ALL studies are manufacturer-funded with lead author = CMO of Armenta. Zero independent replication. The controlled trial data (70.5% recovery) cannot be relied upon.

6. **5B ADEP killed but ZG-series noted.** External review killed ADEP scaffold (mammalian ClpP activation) but noted ZG-series non-ADEP selective ClpP activators as a future opportunity. This is included as a conditional/pipeline item, not a current portfolio asset.

---

*Evidence register compiled from Phases 1-4 and six external reviewers. Citations marked "to be verified" require primary source confirmation before partner presentation. All evidence tiers per Quality Standard 1. Species/model tags per Quality Standard 6.*
